(Q37848694)

24 August 2017

1 reference

title

Therapeutic approaches in myositis (English)

1 reference

24 August 2017

2

Chester V Oddis

1 reference

24 August 2017

1

Rohit Aggarwal

1 reference

24 August 2017

1 June 2011

1 reference

Current Rheumatology Reports

24 August 2017

1 reference

24 August 2017

13

1 reference

24 August 2017

3

1 reference

24 August 2017

182-191

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-011-0172-z

24 August 2017

0 references

cites work

Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Tacrolimus in refractory polymyositis with interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Treatment of antisynthetase-associated interstitial lung disease with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Mycophenolate mofetil treatment in resistant myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Mycophenolate mofetil for interstitial lung disease in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Rituximab treatment of the anti-synthetase syndrome: a retrospective case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Reliability and validity of the myositis disease activity assessment tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0172-Z

Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis.

21 January 2018

1 reference

12 December 2020

Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis

1 reference

12 December 2020

[Nation-wide survey for the treatment with cyclosporin A of interstitial pneumonia associated with collagen diseases]

1 reference

12 December 2020

Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases

1 reference

12 December 2020

A pilot trial of rituximab in the treatment of patients with dermatomyositis

1 reference

12 December 2020

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial

1 reference

12 December 2020

Cyclophosphamide pulse therapy for rapidly progressive interstitial pneumonia in dermatomyositis. A new possibility for rescue?

1 reference

12 December 2020

Pilot trial of etanercept in the treatment of inclusion-body myositis

1 reference

12 December 2020

Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens

1 reference

12 December 2020

Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial

1 reference

12 December 2020

Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis?

1 reference

12 December 2020

Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases

1 reference

12 December 2020

Mycophenolate mofetil in dermatomyositis: is it safe?

1 reference

12 December 2020

Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy

1 reference

12 December 2020

Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis

1 reference

12 December 2020

The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy

1 reference

12 December 2020

Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study

1 reference

12 December 2020

Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results?

1 reference

12 December 2020

Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy

1 reference

12 December 2020

Use of etanercept in the treatment of dermatomyositis: a case series

1 reference

12 December 2020

Cyclosporine A as treatment of esophageal involvement in dermatomyositis

1 reference

12 December 2020

Rituximab for refractory polymyositis: an open-label prospective study.

1 reference

12 December 2020

10.1007/S11926-011-0172-Z

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21365210